A New Paclitaxel Formulation Based on Secretome Isolated from Mesenchymal Stem Cells Shows a Significant Cytotoxic Effect on Osteosarcoma Cell Lines

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Sep 28

PMID 37765308

Authors

Alessia Giovanna Santa Banche Niclot

Elena Marini

Ivana Ferrero

Francesco Barbero

Elena Rosso

Ivana Fenoglio

Alessandro Barge

Augusto Pessina

Valentina Cocce

Francesca Paino

Katia Mareschi

Franca Fagioli

Affiliations

Soon will be listed here.

Abstract

Background: Osteosarcoma (OS) represents a rare cancer with an unfavorable prognosis that needs innovative treatment. The aim was to isolate a secretome from mesenchymal stem cells (MSCs) that are treated with paclitaxel (PTX)-containing microvesicles as a drug delivery system and analyze its cytotoxic effects on OS cell lines (SJSA, MG63, and HOS).

Methods: Three batches of secretome (SECR-1, SECR-2, and SECR-3) were produced from three bone marrow (BM) MSCs samples treated for 24 h with 15 µg/mL of PTX or with a standard medium. The viability of the OS cell lines after 5 days of exposure to SECR-1-2-3 (pure and diluted to 1:2 and 1:4) was analyzed with an MTT assay. The same SECR batches were analyzed with high-performance liquid chromatography (HPLC) and with a nanoparticle tracking assay (NTA).

Results: A statistically significant decrease in the viability of all OS cell lines was observed after treatment with SECR-PTX 1-2-3 in a dose-response manner. The NTA analyses showed the presence of nanoparticles (NPs) with a mean size comparable to that of extracellular vesicles (EVs). The HPLC analyses detected the presence of PTX in minimal doses in all SECR batches.

Conclusions: This proof-of-concept study showed that the conditioned medium isolated from MSCs loaded with PTX had a strong cytotoxic effect on OS cell lines, due to the presence of EV and PTX.

Citing Articles

Research hotspots and trends of mesenchymal stem cell-derived extracellular vesicles for drug delivery: a bibliometric and visualization analysis from 2013 to 2023.

Zhao T, Mu Y, Deng H, Liang K, Zhou F, Lin Q Front Cell Dev Biol. 2024; 12:1412363.

PMID: 39539963 PMC: 11557358. DOI: 10.3389/fcell.2024.1412363.

References

Yoon S, Moon Y, Chun H, Yang D . Doxorubicin·Hydrochloride/Cisplatin-Loaded Hydrogel/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo. Nanomaterials (Basel). 2019; 9(12). PMC: 6956151. DOI: 10.3390/nano9121652. View

Jafarinia M, Alsahebfosoul F, Salehi H, Eskandari N, Ganjalikhani-Hakemi M . Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Novel Cell-Free Therapy. Immunol Invest. 2020; 49(7):758-780. DOI: 10.1080/08820139.2020.1712416. View

Lisini D, Nava S, Frigerio S, Pogliani S, Maronati G, Marcianti A . Automated Large-Scale Production of Paclitaxel Loaded Mesenchymal Stromal Cells for Cell Therapy Applications. Pharmaceutics. 2020; 12(5). PMC: 7284468. DOI: 10.3390/pharmaceutics12050411. View

Anderson M . Update on Survival in Osteosarcoma. Orthop Clin North Am. 2015; 47(1):283-92. DOI: 10.1016/j.ocl.2015.08.022. View

Grunewald T, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F . Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020; 12(11):e11131. PMC: 7645378. DOI: 10.15252/emmm.201911131. View

Scioli M, Artuso S, DAngelo C, Porru M, DAmico F, Bielli A . Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth. PLoS One. 2018; 13(9):e0203426. PMC: 6128546. DOI: 10.1371/journal.pone.0203426. View

Pessina A, Bonomi A, Cocce V, Invernici G, Navone S, Cavicchini L . Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One. 2011; 6(12):e28321. PMC: 3243689. DOI: 10.1371/journal.pone.0028321. View

Bari E, Perteghella S, Catenacci L, Sorlini M, Croce S, Mantelli M . Freeze-dried and GMP-compliant pharmaceuticals containing exosomes for acellular mesenchymal stromal cell immunomodulant therapy. Nanomedicine (Lond). 2019; 14(6):753-765. DOI: 10.2217/nnm-2018-0240. View

Babajani A, Soltani P, Jamshidi E, Farjoo M, Niknejad H . Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer. Front Bioeng Biotechnol. 2020; 8:748. PMC: 7390947. DOI: 10.3389/fbioe.2020.00748. View

10.

Sevelda P, Mayerhofer K, Obermair A, Stolzlechner J, Kurz C . Thrombosis with paclitaxel. Lancet. 1994; 343(8899):727. DOI: 10.1016/s0140-6736(94)91602-0. View

11.

Kim M, Haney M, Zhao Y, Mahajan V, Deygen I, Klyachko N . Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2015; 12(3):655-664. PMC: 4809755. DOI: 10.1016/j.nano.2015.10.012. View

12.

Lenna S, Bellotti C, Duchi S, Martella E, Columbaro M, Dozza B . Mesenchymal stromal cells mediated delivery of photoactive nanoparticles inhibits osteosarcoma growth in vitro and in a murine in vivo ectopic model. J Exp Clin Cancer Res. 2020; 39(1):40. PMC: 7036176. DOI: 10.1186/s13046-020-01548-4. View

13.

Khan M, Adil S, Olson A . The role of mesenchymal stem cells in oncology and regenerative medicine. Future Oncol. 2016; 13(9):821-831. DOI: 10.2217/fon-2016-0264. View

14.

Bari E, Perteghella S, Silvestre D, Sorlini M, Catenacci L, Sorrenti M . Pilot Production of Mesenchymal Stem/Stromal Freeze-Dried Secretome for Cell-Free Regenerative Nanomedicine: A Validated GMP-Compliant Process. Cells. 2018; 7(11). PMC: 6262564. DOI: 10.3390/cells7110190. View

15.

Hingorani P, Janeway K, Crompton B, Kadoch C, Mackall C, Khan J . Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genet. 2016; 209(5):182-94. PMC: 5497490. DOI: 10.1016/j.cancergen.2016.03.004. View

16.

Ottaviani G, Jaffe N . The epidemiology of osteosarcoma. Cancer Treat Res. 2010; 152:3-13. DOI: 10.1007/978-1-4419-0284-9_1. View

17.

Walker F . Paclitaxel (TAXOL): side effects and patient education issues. Semin Oncol Nurs. 1993; 9(4 Suppl 2):6-10. DOI: 10.1016/s0749-2081(16)30036-5. View

18.

Ingley K, Maleddu A, Le Grange F, Gerrand C, Bleyer A, Yasmin E . Current approaches to management of bone sarcoma in adolescent and young adult patients. Pediatr Blood Cancer. 2021; 69(2):e29442. DOI: 10.1002/pbc.29442. View

19.

Mareschi K, Marini E, Santa Banche Niclot A, Barone M, Pinnetta G, Adamini A . A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions. Int J Mol Sci. 2022; 23(6). PMC: 8953582. DOI: 10.3390/ijms23063234. View

20.

Loebinger M, Janes S . Stem cells as vectors for antitumour therapy. Thorax. 2010; 65(4):362-9. PMC: 3401681. DOI: 10.1136/thx.2009.128025. View